Sirnaomics
Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007) developing RNA interference therapeutics across oncology, medical aesthetics, and cardiometabolic diseases using two proprietary delivery platforms, PNP and GalAhead™.
- Company typePublic
- Founded2007
- HeadquartersGaithersburg, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sirnaomics does
Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007 in Maryland, USA) developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiometabolic diseases. The company is built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle), a histidine-lysine polypeptide system using a proton sponge mechanism that achieves 30%–50% endosomal escape efficiency and enables extrahepatic delivery to skin, adipose, muscle, eye, and solid tumors; and GalAhead™, a GalNAc-siRNA conjugate platform with programmable long-acting administration for liver-targeted indications. Its 14+ candidate pipeline includes core product STP705 (dual TGF-β1/COX-2 siRNA in PNP) in Phase II for cutaneous squamous cell carcinoma in situ (88.9% complete histological clearance) and in development for fat remodeling, plus STP707 (Phase I solid tumors), STP122G (Phase I anticoagulation, Factor XI), and an expanding GalAhead™/muRNA™ dual-target portfolio covering PCSK9, ANGPTL3, APOC3, AGT, TTR, and complement factors.
The company does not yet have any commercialized products. Revenue is expected to flow from product sales following regulatory approvals, supplemented by potential licensing/royalty income from strategic partners. Operations span US headquarters (Germantown, MD), Hong Kong (financing and IR hub), Suzhou (China R&D hub), Guangzhou (clinical manufacturing), Beijing (China clinical center), and Boston (US BD center), supporting a dual US/China clinical development strategy. STP705 has been granted FDA Orphan Drug Designation for cholangiocarcinoma and primary sclerosing cholangitis, creating regulatory exclusivity in those indications.
Sirnaomics' go-to-market is event- and partnership-driven: CEO Dr. H. Fai Poon presents at CPHI China, I-RNA Summit, and IMCAS World Summit; the company engages clinical trial sites globally and has entered strategic commercialization partnerships, most notably with Bloomage Biotech (HKD 138M investment, ~9.44% stake in 2025) to accelerate aesthetics, longevity, and regenerative medicine pipelines. Capital structure is anchored by the HKEX listing (December 2021, "Asia's first RNAi therapeutics stock"), a $105M Series E (2021), and ongoing insider/institutional backing including Dr. Poon's HK$58.9M subscription (2024) and an HK$8M HKSTP grant (2023).
Sirnaomics firmographics
Firmographics- Name
- Sirnaomics
- Legal name
- Sirnaomics Ltd.
- Website
- https://sirnaomics.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257; founded 2007) developing RNA interference therapeutics across oncology, medical aesthetics, and cardiometabolic diseases using two proprietary delivery platforms, PNP and GalAhead™.
- Ownership category
- akta.pro rank
Sirnaomics industry classification
Industry- Product category
- RNAi Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industries
- RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)
Keywords
Where Sirnaomics is headquartered
LocationHeadquarters
- HQ city
- Gaithersburg
- HQ country
- United States
- HQ region
- North America
Offices9 records
Markets served
Sirnaomics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- RNAi Therapeutic Pipeline Commercialization: As a clinical-stage biopharmaceutical company, Sirnaomics is developing multiple RNAi therapeutic candidates across oncology, medical aesthetics, and cardiovascular diseases. The company has not yet commercialized any products. Revenue will be generated through product sales following regulatory approvals. Key pipeline products include STP705 (Phase II for isSCC, BCC, fat remodeling), STP707 (Phase I for solid tumors), and STP122G (Phase I for anticoagulation).
- Strategic Partnerships and Licensing: The company may generate revenue through strategic partnerships, co-development agreements, and potential out-licensing of its proprietary delivery platforms (PNP, GalAhead™) and drug candidates to larger pharmaceutical companies. The collaboration with Bloomage Biotech represents a step toward pipeline commercialization in aesthetics and longevity.
- Government Grants and Subsidies: Sirnaomics receives government funding to support clinical development. The company received an HK$8 million subsidy from HKSTP to support clinical trials of STP122G for anticoagulation therapy.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Sirnaomics product offering
Product offeringCore offering
Sirnaomics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiovascular/metabolic diseases. Its product portfolio comprises 14+ siRNA drug candidates built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle) for extrahepatic delivery and GalAhead™ (GalNAc-based) for liver-targeted, long-acting delivery. Core clinical asset STP705 (dual TGF-β1/COX-2 inhibitor) achieved 88.9% complete histological clearance in Phase IIb isSCC trials.
Product overview
Sirnaomics is a clinical-stage biopharmaceutical company (HKEX: 2257) specializing in RNA interference (RNAi) therapeutics with two proprietary delivery platforms: the PNP (Polypeptide Nanoparticle) platform for extrahepatic tissue targeting (skin, adipose, muscle, solid tumors) and the GalAhead™ (GalNAc) platform for liver-targeted delivery. The company's product portfolio includes multiple siRNA drug candidates spanning oncology (STP705, STP707, STP355, STP369), cardiovascular/metabolic diseases (STP122G, STP125G, STP136G, STP237G, STP247G, STP251G, STP271G, STP152G), and complement-mediated diseases (STP144G, STP145G, STP146G). Core product STP705 is in Phase II for skin cancers with 88.9% histological clearance rate. The company also operates an AODC platform for antibody-oligonucleotide conjugates and a muRNA™ dual-target technology for multi-target silencing.
Differentiator
Problem solved
Functional benefit
Brands
- PNP Platform: Polypeptide Nanoparticle delivery platform for extrahepatic RNAi delivery
- GalAHead™
Products and services
- STP705 Dual TGF-β1/COX-2 siRNA therapeutic using PNP delivery platform for intralesional administration; indicated for cutaneous squamous cell carcinoma in situ (isSCC), basal cell carcinoma (BCC), and fat remodeling for medical aesthetics. Achieved 88.9% complete histological clearance in Phase IIb isSCC trial with ≥24 months shelf-life stability at 2-8°C. Holds FDA Orphan Drug Designation for cholangiocarcinoma (CCA) and primary sclerosing cholangitis (PSC).
- STP707 TGF-β1/COX-2 dual inhibitor using PNP-IV delivery platform for intravenous administration; indicated for solid tumors and liver cancer. Currently in Phase I clinical stage.
- STP355 siRNA treatment targeting TGF-β1 and VEGFR2 proteins using PNP delivery platform; indicated for breast cancer, melanoma, and colorectal cancer. Preclinical stage.
- STP369 siRNA treatment targeting BCL-xL and MCL-1 proteins using PNP delivery platform; indicated for head and neck cancer and bladder cancer, with exploration of combination therapy with platinum-based chemotherapy cisplatin. Preclinical stage.
- STP122G Factor XI-targeted siRNA using GalAhead™ (GalNAc) delivery platform for subcutaneous administration; indicated as anticoagulant for stroke patients and orthopedic surgery patients. Early clinical stage with U.S. IND submitted.
- STP125G APOC3-targeted siRNA using GalAhead™ platform for treating hypertriglyceridemia and familial hypertriglyceridemia. Preclinical stage.
- STP144G Complement Factor B-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
- STP145G Complement Factor C5-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
- STP146G Complement Factor C3-targeted siRNA using GalAhead™ platform for complement-mediated diseases. Preclinical stage.
- STP152G TTR (transthyretin)-targeted siRNA using GalAhead™ platform for ATTR amyloidosis. Preclinical stage.
- STP136G AGT (angiotensinogen)-targeted siRNA using GalAhead™ platform for hypertension. Preclinical stage.
- STP247G Dual-target siRNA targeting Complement Factor CFB/C5 using GalAhead™ muRNA platform for subcutaneous administration; indicated for complement-mediated diseases. Preclinical stage.
- STP251G Dual-target siRNA targeting APOC3/TMPRSS6 using GalAhead™ muRNA platform for subcutaneous administration; indicated for hemochromatosis and hypertriglyceridemia. Preclinical stage.
- STP237G Dual-target siRNA targeting AGT/APOC3 using GalAhead™ platform; indicated for hypertension and hypertriglyceridemia. Preclinical stage.
- STP271G Dual-target siRNA targeting PCSK9/ANGPTL3 using GalAhead™ platform; indicated for hyperlipidemia/hypertriglyceridemia. Preclinical stage.
Quantifiable outcome
- 88.9% complete histological clearance rate in isSCC Phase IIb trials
- +4 more outcomes
Companies that use Sirnaomics
Customer profileSegments4 records
Ideal customer profiles3 records
Sirnaomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Sirnaomics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered strategic and core.
- Peking University (Professor Tang Xinjing's team)strategicJoint application for Lingang Laboratory scientific research task project titled 'Construction of Innovative One Drug, Two Targets muRNA Nucleic Acid Drugs and Preclinical Research Targeting Dyslipidemia'. Project focuses on PCSK9, ANGPTL3, and DGAT2 targets for treating dyslipidemia using Sirnaomics' muRNA dual-target RNAi technology and GalAhead delivery system.
- Bloomage BiotechcoreStrategic equity investment of approximately HKD 138 million giving Bloomage about 9.44% of Sirnaomics' shares. Investment aims to accelerate development in aesthetics, longevity, regenerative medicine, and other pipelines through collaboration on delivery platforms and biologics. Represents a key strategic partnership for pipeline commercialization in specific therapeutic areas.
Scale indicators12 records
Recent moves7 records
Expansion highlights5 records
Sirnaomics competitors and assessment
Company assessmentRegional players
- Suzhou Ribo Life Science: China-based RNAi therapeutics company developing siRNA candidates for cardiovascular, metabolic and infectious diseases using proprietary RIBO-GalSTAR® GalNAc delivery platform. Comparable to Sirnaomics as an Asia-based RNAi competitor with similar cardiometabolic focus and platform-based approach.
Direct peers
- Wave Life Sciences: Clinical-stage RNA therapeutics company using stereopure oligonucleotide chemistry and siRNA/ASO platforms with extrahepatic and CNS delivery ambitions. Comparable to Sirnaomics in platform-driven RNA therapeutics strategy, pursuit of tissues outside the liver, and early-to-mid clinical stage development.
- Alnylam Pharmaceuticals: The global leader in RNAi therapeutics with multiple commercialized assets (Onpattro, Givlaari, Oxlumo, Amvuttra) primarily using GalNAc liver-targeted delivery. Sirnaomics competes with Alnylam in RNAi platform technology, cardiometabolic indications (PCSK9, TTR, APOC3) and overall siRNA chemistry/CMC know-how, though Sirnaomics differentiates on extrahepatic delivery via PNP.
- Ractigen Therapeutics: China-based clinical-stage RNAi therapeutics company developing siRNA candidates for neuromuscular and rare diseases using proprietary delivery approaches. Comparable to Sirnaomics as an Asia-headquartered RNAi platform competitor, particularly relevant given Sirnaomics' own US-China operations.
- Arcturus Therapeutics: Clinical-stage RNA medicines company developing both mRNA vaccines/therapeutics and siRNA candidates with proprietary LUNAR® delivery technology. Comparable to Sirnaomics in combining siRNA and mRNA delivery ambitions and platform-based pipeline strategy.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with multiple partnered programs in cardiometabolic, liver and pulmonary indications, using both GalNAc and TRiM™ delivery platforms. Sirnaomics and Arrowhead overlap on liver-targeted GalNAc siRNA development (PCSK9, APOC3, AGT), pipeline breadth and clinical stage, making Arrowhead one of the closest comparables for the GalAhead™ platform.
- Silence Therapeutics: Clinical-stage RNAi therapeutics company developing GalNAc-conjugated siRNAs for cardiovascular and rare diseases (notably SLN360 for LP(a) and SLN124 for iron overload). Directly comparable to Sirnaomics on GalAhead™-style liver-targeted siRNA delivery, cardiometabolic focus, and clinical stage.
Broad incumbents
- BioNTech: Global biopharmaceutical company best known for mRNA COVID vaccines, with expanding pipeline into cancer immunotherapies and RNA therapeutics. Comparable to Sirnaomics as a broader RNA medicines player, though BioNTech's commercial scale, mRNA focus and immuno-oncology pipeline make it a broader incumbent rather than a direct RNAi competitor.
- Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) leader with multiple commercialized products (Spinraza, Tegsedi, Waylivra) and a broader RNA-targeted drug portfolio. Comparable to Sirnaomics as a pioneer in RNA-targeted therapeutics but operates with a different chemistry (ASO vs siRNA) and broader indication coverage.
Others
- Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk in 2021, Dicerna was a clinical-stage RNAi company developing GalNAc-conjugated siRNAs for cardiometabolic and rare diseases — closely mirroring the GalAhead™ platform strategy. Now operates within Novo Nordisk's broader RNAi and cardiometabolic pipeline, representing the strategic acquirer profile Sirnaomics' liver-targeted assets could attract.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Sirnaomics social profiles
Digital presenceSirnaomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sirnaomics leadership team
Management profileNumber of profiles
Profiles7 records
Sirnaomics subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sirnaomics funding detail
Funding detailFunding overview
Funding rounds10 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sirnaomics M&A and investment
M&A and investmentM&A
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sirnaomics
What does Sirnaomics do?
Sirnaomics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics for oncology, medical aesthetics, and cardiovascular/metabolic diseases. Its product portfolio comprises 14+ siRNA drug candidates built on two proprietary delivery platforms: PNP (Polypeptide Nanoparticle) for extrahepatic delivery and GalAhead™ (GalNAc-based) for liver-targeted, long-acting delivery. Core clinical asset STP705 (dual TGF-β1/COX-2 inhibitor) achieved 88.9% complete histological clearance in Phase IIb isSCC trials.
Is Sirnaomics a public or private company?
Sirnaomics is a public company. It is classified as public and is currently operating.
When was Sirnaomics founded?
Sirnaomics was founded in 2007. It employs 51 to 100 people.
Where is Sirnaomics based?
Sirnaomics is headquartered in Gaithersburg, United States, in the North America region.
How does Sirnaomics make money?
Three revenue lines are on record. RNAi Therapeutic Pipeline Commercialization is the primary driver. The others are strategic Partnerships and Licensing and government Grants and Subsidies.
Who are Sirnaomics's main competitors?
Suzhou Ribo Life Science is listed as a regional player. Direct peers are Wave Life Sciences, Alnylam Pharmaceuticals, Ractigen Therapeutics, Arcturus Therapeutics, Arrowhead Pharmaceuticals and Silence Therapeutics. Broad incumbents are BioNTech and Ionis Pharmaceuticals. Dicerna Pharmaceuticals (Novo Nordisk) is listed as an others.
Does Sirnaomics have an API?
No public API is recorded for Sirnaomics.
What industry is Sirnaomics in?
Sirnaomics's product category is RNAi Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAE, RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry). Its NAICS code is 325414 and its SIC code is 2836.